Fidarestat. Sanwa Kagaku/NC Curex/Sankyo.
Fidarestat is an aldose reductase inhibitor being co-developed by Sanwa Kagaku, NC Curex (a joint venture company created by Japan Energy and Kaken) and Sankyo, for the potential treatment of diabetic neuropathy.
Giannoukakis
Nick
N
University of Pittsburgh School of Medicine, Diabetes Institute, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA. ngiann1@pitt.edu
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000818:Animals; D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003929:Diabetic Neuropathies / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D048289:Imidazolidines; D013329:Structure-Activity Relationship
D004791:Enzyme Inhibitors; D007093:Imidazoles; D048289:Imidazolidines; C077139:fidarestat; D000449:Aldehyde Reductase